TheranosticTrials.org

Clinical Trial · NCT06792097

Ga-68 Dolacga PET Scan in HCC Under RFA

Overview

This study aims to investigate the use of Ga-68 Dolacga PET scan technology to assess treatment response and liver function changes in patients of early-stage liver cancer receiving RFA. The main questions it aims to answer are: 1. How to assess treatment response and liver function changes in hepatocellular carcinoma patients undergo RFA via Ga-68 Dolacga PET scan? 2. Compared with computed tomography (CT) scans, how effective is Ga-68 Dolacga PET scan for treatment response assessment? 3. What is the correlation between Ga-68 Dolacga PET scan findings and patient treatment outcomes by tracking liver function and tumor recurrence after RFA? Participants will: 1. Undergo Ga-68 Dolacga PET scans and computed tomography before and one month after RFA treatment, followed by monitoring every three months thereafter. 2. Total liver functional volume and residual liver functional volume are obtained from Ga-68 Dolacga PET scan

Sponsor

National Taiwan University Hospital

Contacts

Geng-Hao Bai, MD (CONTACT)

b101105010@gmail.com

+886953861233

Ja-Der Liang, MD, phD (CONTACT)

jdliangntu@ntu.edu.tw

+886 0223123456

ClinicalTrials.gov

NCT06792097

Drug / Compound

Dolacga

Isotope(s):
Target(s):
  • Asialoglycoprotein Receptor
Ligand Class: Peptides

Eligibility

Inclusion

  • A single liver tumor, ≤ 2 cm, classified as BCLC stage 0 (very early stage).
  • Patients with hepatocellular carcinoma (BCLC stage 0 and stage A) eligible for radiofrequency ablation (RFA) treatment exhibit the following characteristics:
  • Tumors ≤ 3 in number, each ≤ 3 cm, or a single tumor ≤ 5 cm, classified as BCLC stage A (early stage) liver cancer.
  • ECOG performance status of 0.

Exclusion

  • Vascular invasion (e.g., portal vein obstruction).
  • Extrahepatic tumor spread.
  • Intermediate (BCLC B stage) and advanced (BCLC C stage) liver cancer patients:
  • Target lesions previously treated with local therapies, including surgical resection, percutaneous ethanol injection (PEI), or liver transplantation.
  • Early-stage liver cancer (BCLC A stage):